Concise Prescribing Info
Listed in Dosage.
Dosage/Direction for Use
Adult: Ophth Mydriasis and cycloplegia for refraction As 0.5, 1, or 2% soln: Instill 1 drop to each eye 30-60 min prior to procedure, may repeat after 5-15 min if necessary. Iritis; Uveitis As 0.5%, 1% soln: Instill 1 drop onto the affected eye(s) 6-8 hrly. Deeply pigmented eyes may require higher strength.
Confirmed or suspected narrow-angle glaucoma.
Special Precautions
Patient w/ Down syndrome. Debilitated patients. Childn w/ spastic paralysis or brain damage. Pregnancy and lactation. Patient Counselling This drug may cause transient blurring of vision and increased sensitivity to light, if affected, do not drive or operate machinery. Remove contact lenses prior to admin and reinsert after 15 min. Monitoring Parameter Perform tonometric examination prior to use of drug.
Adverse Reactions
Significant: Transient increase in intraocular pressure, ocular irritation and burning sensation, CNS disturbance, psychotic reactions. Nervous: Insomnia, drowsiness, ataxia, hallucination, hyperactivity, incoherent speech, restlessness, seizure. CV: Tachycardia. Ophthalmologic: Accommodation disturbance, intolerance to bright light, stinging, blurring of vision, punctal stenosis. Dermatologic: Burning sensation of the skin.
Drug Interactions
May interfere w/ ocular antihypertensive action of carbachol, pilocarpine, or ophthalmic cholinesterase inhibitors.
CIMS Class
ATC Classification
S01FA04 - cyclopentolate ; Belongs to the class of anticholinergics used as mydriatics and cycloplegics.
Disclaimer: This information is independently developed by CIMS based on cyclopentolate from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in